Adenovirus Serotype 5 Vectors with Tyr3-Octreotate Modified as a Virulytic Oncotherapy Agent in AGS Cells
Background: Oncolytic viral therapy is known as a new promising strategy to treat cancer. Oncolytic viruses (OVs) can replicate in cancer cells, and beside this primary effect, OVs can also stimulate the immune system. Moreover, Adenovirus serotype 5 (Ad5) is widely used as an oncolytic agent for cancer therapy. The present study aimed to make a change in the adenovirus fiber area.
Methods: The tyr3-octreotate sequence was inserted into the HI-loop in the adenovirus fiber knob. In addition, recombinant virus was transferred to the HEK-293 packaging cells using the calcium phosphate method; therefore, the new virus was prepared. Accordingly, virus titer was calculated using the TCID50 method. Afterward, recombinant adenovirus and wild-type 5 strain were transferred to perform against human adenocarcinoma gastric cell line (AGS). Subsequently, they were evaluated for cytopathic effects, and the manipulated virus was then confirmed Using PCR and sequencing.
Results & Conclusions: In this regard, the obtained results showed that the recombinant adenovirus has a greater ability in infecting AGS cells compared to the wild-type adenovirus. Our data suggest that, modification of Ad5 with tyr3-octreotate expands its usage as an oncolytic agent against the AGS cells.
Authors of articles published in Journal of BioScience and Biotechnology retain the copyright of their articles. The journal/publisher is not responsible for subsequent uses of the work. It is the author's responsibility to bring an infringement action if so desired by the author.
- copyright, and other proprietary rights relating to the article, such as patent rights;
- the right to use the substance of the article in future own works, including lectures and books;
- the right to reproduce the article for own purposes, provided the copies are not offered for sale;
- the right to self-archive the article.